Vertex secured a major milestone for its CRISPR sickle cell drug, with potential annual revenue exceeding $5 billion, bolstered by international partnerships with the U.K. and China.
1 report, 1 independent
Updated Jun 25
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Vertex secured a major milestone for its CRISPR sickle cell drug, with potential annual revenue exceeding $5 billion, bolstered by international partnerships with the U.K. and China.